Please assess the completion status of the following clinical trial:

Trial Title: AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Recurrent symptomatic Atrial Fibrillation (AF)~2. Age 50-80 years with persistent AF (≥1 of AF episode lasting more than a week or requiring cardioversion)~Exclusion Criteria:~1. Permanent atrial fibrillation~2. Prior continuous use of amiodarone of more than 2 weeks.~3. Prior catheter ablation for AF.~4. Have a documented resting heart (while awake) of \< 50 beats per minute.~5. Have a known severe liver disease.~6. Are deemed not suitable for CA (LA size, comorbidities...).~7. Have a severe valvular disease or have a mechanical mitral prosthesis.~8. Have a life-expectancy of less than 2 years.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Medical therapy (Type: ACTIVE_COMPARATOR): Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
- Catheter ablation (Type: ACTIVE_COMPARATOR): A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )

Based on this trial design, predict the completion outcome and termination type (if applicable).